Nocturnal, sleeping IOP keeps ophthalmologists up at night

Article

There is much to be learned about nocturnal-and, more importantly, sleeping-IOP if ophthalmologists are going to optimize glaucoma therapies, said Yaniv Barkana, MD, Department of Ophthalmology, Assaf Harofeh Medical Center, Israel.

There is much to be learned about nocturnal-and, more importantly, sleeping-IOP if ophthalmologists are going to optimize glaucoma therapies, said Yaniv Barkana, MD, Department of Ophthalmology, Assaf Harofeh Medical Center, Israel.

"What happens to IOP during the one-third of our lives that we're asleep? We know from several recent studies, and some not-so-recent, that supine, nighttime IOP is higher than daytime sitting IOP, in some cases on the order of 4 mm," Dr. Barkana said. "This may mean that glaucoma progression takes place while we are sleeping."

Unfortunately, Dr. Barkana said, there is not any single best way to measure IOP during sleep.

"Keep in mind that measuring nocturnal IOP is not the same as measuring sleeping IOP," he said. "We can measure IOP after waking patients, but even if we wake them gently, the change from sleeping to waking changes the equation."

Having an analysis of sleeping IOP could have implications for making a diagnosis of normal-tension glaucoma and increase the understanding of the mechanism of normal-tension glaucoma, according to Dr. Barkana. It may also alter treatment regimens.

"It may be that we choose to design and pursue therapies designed to blunt the sleeping IOP rise," he said.

Tools may become available for clinicians in the near future to help answer the question of what IOP is doing as we sleep, Dr. Barakana said. Implantable or contact lens-mounted monitors may allow for continuous IOP monitoring that may lead to new ways of thinking about glaucoma management.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.